English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/169901
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

New tacrines as anti-alzheimer’s disease agents. The (benzo)chromeno-pyranotacrines

AuthorsOset-Gasque, María Jesús; Marco-Contelles, José
KeywordsTacrine, ChromenoPyranoTacrines, Multi-Target-Directed (MTD) Ligands, Alzheimer’s disease, Aβ-amyloid, Reactive oxygen species
Issue Date2017
PublisherBentham Science Publishers
CitationCurrent Topics in Medicinal Chemistry 17: 3349- 3360 (2017)
AbstractTacrine was the first drug approved by FDA (US) for the treatment of Alzheimer’s disease suffering patients. Nowadays, this agent has been withdrawn from the clinics due to secondary effects, which, most importantly, include hepatotoxicity. However, the research on new tacrine analogues devoid of these therapeutically undesirable effects, but benefiting of their high and well known positive cholinergic power, has produced a number of new non-hepatotoxic tacrines. In this context, our laboratory has recently prepared a new set of heterocyclic tacrines by changing the benzene ring present in tacrine by appropriate heterocyclic motifs. Based on this approach, in this review we summarize the results that we have found in the ChromenoPyranoTacrines, one of the families of tacrine analogues. This highlights their pharmacological profile, such as their cholinesterase inhibition power, calcium channel blockade, antioxidant capacity, Aβ-anti-aggregating, and neuroprotective properties. As a result of this work we have identified permeable, neuroprotective MTD tacrines racemic hit-tacrines 11-amino-12-(3,4,5-trimethoxyphenyl)-7,9,10,12-tetrahydro-8H-chromeno[2,3-b]quinolin-3-ol (6g) and 14-(3,4-dimethoxyphenyl)-9,11,12,14-tetrahydro-10H-benzo[5,6] chromeno [2,3-b] quinolin-13-amine (7i),devoid of toxic effects and showing potent anti-cholinesterasic properties, that deserve attention and further development in order to find new, and more efficient drugs, for AD therapy.
Publisher version (URL)http://dx.doi.org/10.2174/1568026618666180112155928
Identifiersdoi: 10.2174/1568026618666180112155928
issn: 1568-0266
e-issn: 1873-4294
Appears in Collections:(IQOG) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.